Recent share performance and business context
Edgewise Therapeutics (EWTX) has drawn investor attention after a mixed stretch in the stock, with the price down about 9% over the past month but up roughly 4% over the past 3 months.
Over longer periods, the stock shows a year to date gain of about 32% and a 1 year total return a little above 111%, alongside a 3 year total return a little above 224%, on a market value near US$3.4b.
The company focuses on therapies for muscle disorders, with lead candidate sevasemten in Phase II trials for dystrophinopathies such as Duchenne and Becker muscular dystrophy, alongside early stage programs in hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
See our latest analysis for Edgewise Therapeutics.
The recent share price has eased back, with a 7 day share price return down 7.6% and a 30 day share price return down 8.7%. However, the 1 year total shareholder return of about 111% and 3 year total shareholder return a little above 224% still point to strong longer term momentum.
If the recent pullback in EWTX has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 29 healthcare AI stocks
With Edgewise Therapeutics still loss making and yet valued around US$3.4b, the real question for you is whether recent gains leave upside on the table, or if the stock already reflects much of its potential growth.
Preferred Price to Book Ratio of 6.9x: Is it justified?
Edgewise Therapeutics trades on a P/B of 6.9x, compared with both the US pharmaceuticals industry average of 2.1x and a peer average of 3.9x, so the stock is priced at a clear premium to book value.
The P/B ratio compares the company’s market value to its net assets, which can be a useful reference point for early stage or loss making biopharma stocks where earnings based metrics are less meaningful.
For you as an investor, a 6.9x P/B with no meaningful revenue today and ongoing net losses means the market is assigning a high value to the pipeline and future cash flow potential. That may reflect confidence in forecast annual revenue growth of 66.2%, but it also means expectations are already elevated relative to many sector peers.
Against the broader US pharmaceuticals industry average P/B of 2.1x and a peer average of 3.9x, Edgewise Therapeutics stands out as materially more expensive on this metric. This reinforces that current pricing already embeds a richer view of its prospects than is typical across the group.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book ratio of 6.9x (OVERVALUED).
However, stretched valuation, combined with zero revenue and a reported net loss of US$176.01m, could quickly weigh on sentiment if clinical or funding news disappoints.
Find out about the key risks to this Edgewise Therapeutics narrative.
Next Steps
With sentiment clearly split between rich valuation and promising science, it makes sense to move quickly and test the numbers yourself against the expectations already in the price using 1 key reward and 3 important warning signs
Looking for more investment ideas?
If Edgewise Therapeutics has your attention, do not stop here, there are plenty of other stocks that could suit your goals and risk comfort.
- Target reliable income by scanning 12 dividend fortresses that combine higher yields with businesses focused on ongoing shareholder returns.
- Hunt for potential upside across screener containing 21 high quality undiscovered gems where strong fundamentals have not yet attracted broad market attention.
- Prioritise resilience with 66 resilient stocks with low risk scores that score well on stability so short term volatility is less likely to knock you off course.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com